Clinical Trial Update: A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing safety and efficacy of Upadacitinib versus Dupilumab in adults with moderate to severe atopic dermatitis has completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-02